Press Releases

Date Title and Summary View
Toggle Summary Zosano Pharma Announces Publication of Clinical Data Regarding the Long-term use of Qtrypta™ for the Treatment of Acute Migraine in The Journal of Headache and Pain
FREMONT, Calif. , May 26, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that an article titled, “Long Term Safety, Tolerability, and Efficacy of Intracutaneous Zolmitriptan (M207) in the Acute Treatment of Migraine”
View HTML
Toggle Summary Zosano Appoints Industry Veteran, Kathy McGee, to its Board of Directors
FREMONT, Calif. , May 25, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the appointment of Kathy McGee , an accomplished biopharmaceutical executive, to its board of directors. Ms.
View HTML
Toggle Summary Zosano Pharma Reports First Quarter 2021 Financial Results
FREMONT, Calif. , May 12, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2021 , as well as business highlights. “We have gained clarity from the FDA on the
View HTML
Toggle Summary Zosano Pharma Confirms Plan to Move Forward with Pharmacokinetic Study Following Protocol Review by FDA
– Company Establishes Agreement with Worldwide Clinical Trials to Conduct PK Study – – Anticipates initiating PK Study in June and Completion in Q3 2021 – FREMONT, Calif. , April 26, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today
View HTML
Toggle Summary Zosano Pharma Reports Fourth Quarter and Fiscal Year 2020 Financial Results
FREMONT, Calif. , March 11, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2020 , as well as business highlights.
View HTML
Toggle Summary Zosano Pharma to Present at the H.C. Wainwright Global Life Sciences Conference
FREMONT, Calif. , March 02, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo , will present a company overview at the H.C.
View HTML
Toggle Summary Zosano Pharma Confirms NDA Resubmission Strategy Following Type A Meeting Minutes from FDA
FREMONT, Calif. , Feb. 22, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the company has received the official Type A meeting minutes from the U.S. Food and Drug Administration (“FDA") Division of Neurology II
View HTML
Toggle Summary Zosano Pharma Presents Early-Onset of Action Data for Qtrypta™ in Acute Treatment of Migraines
Review of data from the ZOTRIP trial suggest that Qtrypta showed therapeutic gain at 30 minutes consistent with recently published criteria for evaluating early onset of action All Qtrypta patients who were pain free at 30 minutes were still pain free at 2 hours Observation of pain freedom at 30
View HTML
Toggle Summary Zosano Pharma Announces NDA Resubmission Plans Following Type A Meeting with FDA
FREMONT, Calif. , Feb. 01, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the company completed its Type A meeting with the U.S. Food and Drug Administration (“FDA") Division of Neurology II (the “Division”)
View HTML
Toggle Summary Zosano Pharma Requests Type A Meeting with the FDA to Review Resubmission Plans for Qtrypta™ New Drug Application
FREMONT, Calif. , Jan. 04, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that on December 30, 2020 the company requested a Type A meeting with the U.S. Food and Drug Administration (FDA).
View HTML